Did you know that you can order an eco-conscious burger in Houston? Photo courtesy of Hopdoddy

Hearty Austin-based chain Hopdoddy Burger Bar has unveiled a new lineup of regenerative burgers that are supposed to be better for the planet and the consumer.

The term "regenerative burger" could cause a few head-scratches: Some may think of lab-grown or 3D-printed meat, while others think of plant-based alternatives but it’s neither. It is grass-fed meat, sourced a bit differently. "Regenerative farming" is a term used to describe farming and grazing practices that claim to restore and rebuild degraded soil, resulting in better-quality air and water.

Hopdoddy’s vice president of culinary Matt Schweitzer explained that it all began with with a sense of obligation to do better as a brand for the consumers and the ecosystem.

“We felt like we could really take a stand and look to move our entire supply chain in a regenerative fashion, so we could really be proud of the work we’ve done and we could hopefully leave the animals, the farmers, the ranchers, the native grasslands, and our planet a better place than before we started,” says Schweitzer.

The new menu items include the "Roosevelt Burger" with grass-fed regenerative bison; the "Nashville Hot Sandwich" with regenerative raised chicken; the "Regenerative Royale," which is a play on a classic double quarter-pounder with cheese; the "Mother Nature" with grass-fed regenerative beef; and the "Buffalo Bill" also uses regenerative bison, but appears not to be grass-fed.

The five burgers are available at all Hopdoddy locations nationwide. The beef and bison are sourced from Texas-based regenerative company Force of Nature, while the chicken is from Cooks Venture.

With this launch, Hopdoddy removes all plant-based meat substitutes from its menu, significantly reducing the options for vegans and vegetarians. The company felt the ingredients and ethos of the alternative meats — describing some such as Beyond Meats as "falsely advertised" regarding nutrition in a press release — no longer aligned with its values and mission. However, the house-made veggie patty remains on the signature "El Bandito" burger.

Schweitzer says the regenerative burgers have received positive feedback, as people are excited to know where their food comes from, how it gets to their table, and what type of impact it causes. Regarding the future of regenerative meat, he says there is no doubt it could become mainstream soon.

“I think the flavor profile, the eating experience, the story, the mission, the purpose, really speaks for itself," says Schweitzer. "So, I really think it’s a matter of time until 'regenerative' is talked about in the same way that 'organic,' or 'sustainable,' or those type of buzzwords are talked about."

To further show its commitment to regenerative agriculture, Hopdoddy is also one of the sponsors of Common Ground, a documentary about the pioneers of the regenerative movement, premiering October 4 in Austin. The "uplifting" film, according to a release, features well-known actors Laura Dern, Rosario Dawson, Jason Momoa, Woody Harrelson, Ian Somerhalder, and Donald Glover, emphasizing that this motley crew does share one thing in common: a strong belief in regenerative agriculture.

For more information about the new regenerative burgers, visit hopdoddy.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.